In comparison, the IT dose (1 × 102 TCID50) of MMR in this study is 104- 105-fold lower than that of oncolytic measles and mumps (i.e., 107-108 TCID50) currently used in mouse tumor models and clinical trials (24, 26, 27, 36, 37). The gene discussed is MRC1; the disease is neoplasm.